Buckland Partners Management Co LLC Makes New Investment in Henry Schein, Inc. $HSIC

Key Points

• Buckland Partners Management purchased 12,400 Henry Schein shares during the second quarter, valued at approximately $1.04 million. Institutional investors collectively own 96.62% of the company.
• Analyst sentiment is mixed but generally positive: eight analysts rate HSIC a Buy, six rate it Hold, and one rates it Sell. The consensus rating is Hold, with an average price target of $92.27.
• Henry Schein exceeded quarterly expectations, reporting $1.27 in EPS versus the $1.24 consensus and $3.46 billion in revenue versus $3.37 billion expected. Revenue increased 6.7% year over year, and management guided fiscal 2026 EPS to $5.29–$5.39.

Buckland Partners Management Co LLC purchased a new stake in shares of Henry Schein, Inc. (NASDAQ:HSIC - Free Report) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 12,400 shares of the company's stock, valued at approximately $1,036,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. CYBER HORNET ETFs LLC bought a new position in Henry Schein in the 2nd quarter valued at approximately $25,000. MUFG Securities EMEA plc bought a new stake in shares of Henry Schein in the 2nd quarter worth $27,000. Federated Hermes Inc. purchased a new position in shares of Henry Schein in the fourth quarter worth $32,000. Los Angeles Capital Management LLC purchased a new position in shares of Henry Schein in the fourth quarter worth $37,000. Finally, Trust Co. of Vermont bought a new position in shares of Henry Schein during the second quarter valued at $42,000. Institutional investors own 96.62% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on HSIC shares. Wall Street Zen upgraded Henry Schein from a "hold" rating to a "buy" rating in a report on Monday. Stifel Nicolaus set a $95.00 price target on shares of Henry Schein in a report on Wednesday, August 5th. BTIG Research reiterated a "buy" rating and issued a $100.00 price target on shares of Henry Schein in a research note on Wednesday, August 5th. Barclays reiterated an "overweight" rating and issued a $100.00 price target (up from $86.00) on shares of Henry Schein in a research note on Thursday, August 6th. Finally, Robert W. Baird set a $97.00 price objective on shares of Henry Schein in a research report on Wednesday, May 6th. Eight research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $92.27.

Henry Schein Stock Performance

Shares of NASDAQ HSIC opened at $89.52 on Tuesday. The firm has a 50 day moving average of $85.04 and a 200 day moving average of $79.16. The company has a current ratio of 1.32, a quick ratio of 0.73 and a debt-to-equity ratio of 0.60. The firm has a market capitalization of $9.98 billion, a price-to-earnings ratio of 26.10, a price-to-earnings-growth ratio of 1.71 and a beta of 0.80. Henry Schein, Inc. has a 12-month low of $61.94 and a 12-month high of $92.18.

Henry Schein (NASDAQ:HSIC - Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported $1.27 EPS for the quarter, beating analysts' consensus estimates of $1.24 by $0.03. The business had revenue of $3.46 billion during the quarter, compared to analysts' expectations of $3.37 billion. Henry Schein had a net margin of 2.96% and a return on equity of 15.97%. The firm's revenue was up 6.7% on a year-over-year basis. During the same period in the prior year, the company earned $1.10 earnings per share. Henry Schein has set its FY 2026 guidance at 5.290-5.390 EPS. On average, research analysts anticipate that Henry Schein, Inc. will post 5.35 earnings per share for the current year.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.

Want to see what other hedge funds are holding HSIC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Henry Schein, Inc. (NASDAQ:HSIC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source